ITEMS IN AFP WITH KEYWORD:
Chronic Obstructive Pulmonary Disease
This research fails to determine whether the modest potential benefits of antibiotic prophylaxis in patients with chronic obstructive pulmonary disease outweigh the risk of resistance. Find out more.
Glycopyrrolate is a safe alternative to long-acting muscarinic antagonists delivered by metered-dose inhaler for patients with moderate to severe COPD.
Key clinical questions and their evidence-based answers directly from the journal’s content, written by and for family physicians.
Mar 1, 2019 Issue
Different Durations of Corticosteroid Therapy for COPD Exacerbations [Cochrane for Clinicians]
Treatment of acute exacerbations of COPD with a shorter course of systemic corticosteroids (seven or fewer days) is likely to be as effective and safe as treating with longer courses (more than seven days).
Prophylactic antibiotics may be used to reduce the overall rate of COPD exacerbations and delay their onset. However, the appropriate antibiotic regimen and target population are unclear.
Apr 1, 2018 Issue
Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease [Medicine by the Numbers]
Pneumococcal vaccines had no significant effect on mortality from cardiorespiratory disease when compared with control and had no significant effect on all-cause mortality. Find out more.
Mar 1, 2018 Issue
Written Action Plans for Self-Management of COPD Exacerbations [Cochrane for Clinicians]
Written self-management plans, especially those that include guidance on smoking cessation, increase health-related quality of life in patients with COPD. They also decrease the need for respiratory-related hospital admissions among patients with high or low baseline risk.
Glycopyrrolate is a safe option for maintenance treatment to prevent moderate to severe exacerbations in patients with moderate to severe COPD, with only mild and rare adverse effects.
Learn about the latest recommendations from the Global Initiative for Chronic Obstructive Lung Disease, the American College of Physicians, and the National Institute for Health and Care Excellence.
Umeclidinium is an easy-to-use, once-daily, well-tolerated, and relatively low-cost anti-cholinergic agent for maintenance therapy in patients with moderate to severe COPD.